Total Funding
4
Total FundingSeries A raised
Growth Score
pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
FF Pharma, a biopharmaceutical company, develops anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases.
- Dr. Mark de Boer: CEO and FounderPast Role: Medicxi, Venture Partner
- Ivonne Galesloot: Finance Manager
About the Company
FF Pharma, a biopharmaceutical company, develops anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The functions of CD40 in immune regulation suggest that the CD40 pathway may play a role in diseases in which anomalous immune responses, e.g. autoantibody
production or chronic inflammation, are a feature.
